

LIST OF TABLES

Table No.	Table Captions	Page No.
1.1	Chemical structures, mechanism, and adverse effects of USFDA approved drugs for the treatment of AD.	11
5.1	Cholinesterases (hAChE and hBChE) and hBACE-1 inhibition activity and selectivity index of compounds (Series I and II).	67
5.2	Propidium iodide displacement and predicted BBB permeability.	70
5.3	Pharmacokinetic evaluation after an oral administration of 6j (10 mg/kg, p.o.)	78
5.4	Cholinesterases (hAChE and hBChE) and hBACE-1 inhibition activity and selectivity index of compounds (Series III and IV).	96
5.5	Propidium iodide displacement and predicted BBB permeability (Series III-IV).	99
5.6	Pharmacokinetic evaluation after an oral administration of 13o (10 mg/kg, p.o.)	106